Home › Mercks KEYTRUDA (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1
 

Keywords :   


Mercks KEYTRUDA (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1

2015-12-19 16:55:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KEYNOTE-010 Published in The Lancet and to be Presented at the European Society for Medical Oncology (ESMO) Asia 2015 Congress KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the pivotal KEYNOTE-010 study, the first study of its kind to evaluate the potential of an immunotherapy compared to chemotherapy based on prospective measurement of PD-L1 expression in patients with advanced non-small cell lung cancer (NSCLC). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: of level express cell

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05IMDA launches annual IMDA Awards Competition
20.05Registration opens for FTAs Fall Technical Conference 2024
20.05Voting begins for Colored By INX Can Design Contest
20.05New Study Highlights Biodegradability of Cotton and Cellulosic Microfibers
20.05New ACA-Published Industry Market Analysis for the Paint & Coatings Industry Now Available
20.05Ulta Beauty Launches Same-Day Delivery with DoorDash
20.05Nivea Crmes Limited-Edition Pride Tin Heralds New Initiative with PFLAG
20.05Sheboygan Paint Company Appoints New Technical Sales Representative
More »